Literature DB >> 31942123

Immunohistochemical expression of human telomerase reverse transcriptase in oral cancer and precancer: A case-control study.

Namrata Mishra1, Nishi Tandon1, Naseem Fatima1, Anand N Srivastava1, Nirupma Lal1, Vijay Kumar2.   

Abstract

INTRODUCTION: Telomere Length is critically important in normal cells and telomere shortening in combination with other oncogenic changes- promotes genome instability, potentially stimulating initiation of the early stages of cancer. AIM: The present study was carried out to detect human telomerase reverse transcriptase expression in oral cancer and pre-cancerous lesions by immunohistochemistry.
MATERIALS AND METHODS: An observational study was planned in which a total of 45 biopsy specimen of oral mucosa was obtained. Of these, 15 (33.3%) belonged to normal subjects, 15 (33.3%) to subjects found to have Oral submucousal fibrosis and 15 (33.3%) subjects with Oral squamous cell carcinoma.
RESULTS: Among cases of OSCC, majority was of well differentiated grade (80.0%), only 1 (6.7%) case was poorly differentiated and rest was of moderately differentiated (13.3%) Labelling intensity of OSCC (78.07 ± 22.31) was maximum followed by that of Normal (44.47 ± 6.32) and minimum of OSMF (26.67 ± 15.05) and intergroup difference and between group differences were also found to be significant. Labelling score of OSCC (154.47 ± 94.74) was maximum followed by that of Normal (84.73 ± 51.51) and minimum of OSMF (46.73 ± 44.25) and intergroup difference and between groups differences (Normal vs OSCC, and OSMF and OSCC) were found to be statistically significant.
CONCLUSION: The present study highlights only the discriminating ability of hTERT for differentiating the malignant condition from premalignant and normal mucosa. Hence, further studies on a larger sample size, with inclusion of other premalignant conditions too are recommended in order to understand the pattern of hTERT expression changes. Copyright:
© 2019 Journal of Oral and Maxillofacial Pathology.

Entities:  

Keywords:  Immunohistochemistry; oral squamous cell carcinoma; telomerase; telomere

Year:  2019        PMID: 31942123      PMCID: PMC6948025          DOI: 10.4103/jomfp.JOMFP_133_18

Source DB:  PubMed          Journal:  J Oral Maxillofac Pathol        ISSN: 0973-029X


INTRODUCTION

Cancer is the second most common cause of death in the Western world, after cardiovascular diseases.[1] Oral cancer is one of the most common cancer forms globally. As per an estimate in 2010, worldwide, about 300,000 people were projected to be diagnosed with oral cancer in 2010.[2] Of these, around 126,000 were predicted to die from the disease.[2] In the year 2012, cancers of the oral cavity and pharynx collectively contributed to substantial morbidity and mortality worldwide, with an estimated 526,481 annual incident cases.[3] Among different types of cancers, it ranks sixth in terms of number.[4] Oral cancer mainly affects the poor owing to a higher exposure to risk factors such as the use of tobacco.[5] Although tobacco use and smoking has been recognized as the most common risk factor for oral cancer, there are a number of other factors too that have been shown to play a role in the causation of cancer in general and oral cancer in particular. Other factors frequently cited are ultraviolet light, nutritional and dietary factors, precancerous lesions, immunosuppression, genetic and dental factors. Oral cancer is a multifactorial disease. Exposure to one of the three broad groups of carcinogenic stimuli, namely chemical, physical and viral, is known to induce cancer in genetically and systemically conditioned oral mucosa. In recent years, attempts to weigh the risk of cancer at the molecular level are being made and substantial progress in the knowledge has been made. Recent evidence has shown that telomere biology is central to the maintenance of genomic stability and telomeric dysfunction is thought to be an early stage in carcinogenesis.[6] Telomeres are repeat TTAGGG sequences at the end of linear chromosomes, which guard against loss of genetic material during cellular replication. Due to an inherent end-replication problem, chromosomes are exposed to a potential loss of genetic material, with telomeres acting as a buffer against loss of chromatin. Repeated cell cycles eventually lead to a critically shortened telomere length, signaling cellular senescence and triggering apoptosis. This arrest in proliferation is thought to protect against malignant transformation, and a failure to do so results in catastrophic genomic instability and carcinogenesis.[6] Telomerase is a ribonucleoprotein enzyme that adds a species dependent telomere, which are specialized structures containing unique simple repetitive sequences (TTAGGG in vertebrate) at the end of chromosomes.[78] The enzyme compensates for the end-replication problem and allows cells to proliferate indefinitely.[9] It has been shown that telomerase is activated in most human cancer tissues but not in most normal tissues and tissues adjacent to malignant or benign tumors.[10] In addition, the previous studies have shown that the lack of telomerase activity correlates with critically shortened telomeres and frequent spontaneous cancer remission.[11] Thus, the expression of telomerase is important and may be a rate-limiting step for tumor progression.[10] In recent years, apart from polymerase chain reaction-based telomeric repeat amplification protocol, which is a complicated assessment requiring highly sophisticated equipment and skilled workforce, several immunohistochemical protocols have emerged that have shown to be efficient tools for the detection of telomerase activity in normal tissue and different premalignant and malignant conditions[121314] including oral cancerous and precancerous lesions.[151617] With this background, the present study was carried out with an aim to assess the telomerase expression by the immunohistochemistry in oral precancer and cancer.

MATERIALS AND METHODS

The present case–control study included histopathologically confirmed cases of oral squamous cell carcinoma (OSCC) and oral submucous fibrosis (OSMF) after obtaining the Institutional Ethical Committee clearance (ELMC/R_Cell/EC/2016/54), showing dense fibrous connective tissue with epithelial atrophy. Site-matched normal control tissues were obtained from the noninflamed buccal mucosa during the removal of an impacted third molar of patients attending the hospital. All incisional biopsies were performed under local anesthesia (2% lignocaine). Tissues were fixed in 10% buffered formalin and paraffin embedded.

Study population

After obtaining informed consent, the study was done on patients presenting with complaints of different oral mucosal lesions at the Outpatient Department of Dental and Surgery of Era's Lucknow Medical College and Hospital, Lucknow, as well as King George's Medical University, Lucknow. The biopsy obtained was divided into three groups of oral cancer, precancer and normal healthy oral mucosa, each containing 15 samples histopathologically on the basis of hematoxylin and eosin staining. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) protein telomerase expression was measured immunohistochemically by evaluating the expression of hTERT protein using TERT polyclonal antibody (Elabscience) following the manufacturer's protocol. The sample was brought down to water and dewaxed by three changes of xylene, absolute alcohol, 90%, 70% and 50%, each for 3 min. The slide was kept in antigen retrieval in a Coplin jar. The jar was placed into the pressure cooker on a hot plate. After one whistle, the plate was switched off and waited till all the pressure was released. The pressure cooker was flooded. The slides were not removed till it cooled down. The slides were washed with three changes of distilled water (3 min) and then were washed with three changes of tris buffer. The primary antibody was applied in a moist chamber for 1 h at room temperature. The slides were washed with –three changes of tris buffer. The secondary antibody was applied for 30 min at room temperature. DAB chromogen solution was applied for 5–10 min. The color was observed under a microscope. When the color developed (khaki color), the slide was placed in running tap water for 5 min. Counterstaining with hematoxylin was done for 1 min. Bluing was done with Scott mixture. The slides were dehydrated, cleared and mounted.

Scoring

Cellular localization of the stain was defined as being either nuclear/cytoplasmic/both. The staining intensity (SI) of the samples was graded and assigned numerical scores: 0 – no stain, 1 – mild, 2 – moderate and 3 – intense stain. Three investigators performed the assessment independently and each investigator used the positive control as a standard bench mark. Nuclear labeling indices (LI) were calculated as the percentage of hTERT-stained cells per thousand cells counted. The counting was done using eyepiece graticule under high-power objective (×40). The nuclear labeling scores (LSs) of the samples were determined using the formula LI × SI92. To eliminate the bias in LS, five different sites were counted by two different examiners.

Statistical analysis

The statistical analysis was done using SPSS (Statistical Package for the Social Sciences, version 15; IBM, USA) statistical analysis software. The values were represented in number (%) and mean ± standard deviation. The results with P < 0.05 were considered to be statistically significant.

RESULTS

The age group of patients ranged from 36 to 65 years. Overall mean age was 51.44 ± 6.03 years. The mean age of patients in normal, OSMF and OSCC groups was 52.73 ± 3.59, 49.60 ± 7.39 and 52.00 ± 6.40 years, respectively. On evaluating the data statistically, the difference among the groups was not found to be significant (P = 0.338) [Table 1].
Table 1

Group-wise and age-wise distribution

GroupNumber of cases (%)Mean age (years)
Normal healthy oral mucosa15 (33.33)52.73
OSMF15 (33.33)49.60
OSCC15 (33.33)52.00

OSMF: Oral submucous fibrosis, OSCC: Oral squamous cell carcinoma

Group-wise and age-wise distribution OSMF: Oral submucous fibrosis, OSCC: Oral squamous cell carcinoma

Staining intensity

In 15 cases of OSMF, the SI scores were 0, 1, 2 and 3 in 2 (13.3%), 7 (46.7%), 5 (33.3%) and 1 (16.7%) cases. The median score was 1, and the interquartile range spanned from 1 to 2. Of 15 cases of OSCC, none had score 0, 4 (26.7%) had score 1, 8 (53.3%) had score 2 and 3 (20%) had score 3. The median score was 2, and the interquartile range spanned from 1 to 2. On evaluating the intergroup difference in SI using the Kruskal–Wallis test, they were not found to be significant (P = 0.131) [Tables 2 and 3].
Table 2

Comparison of staining intensity in the three study groups

GroupNumber of casesScore (%)Median score (IQR)

0123
Normal150 (0.0)7 (46.7)4 (26.7)4 (26.7)2 (1-3)
OSMF152 (13.3)7 (46.7)5 (33.3)1 (16.7)1 (1-2)
OSCC150 (0.0)4 (26.7)8 (53.3)3 (20.0)2 (1-2)

OSMF: Oral submucous fibrosis, OSCC: Oral squamous cell carcinoma, IQR: Interquartile range

Table 3

Comparison of staining intensity between malignant and nonmalignant groups

GroupNumber of casesScore (%)Median score (IQR)

0123
Malignant150 (0)4 (26.7)8 (53.3)3 (20.0)2 (1-2)
Nonmalignant302 (6.7)14 (46.7)9 (30.0)5 (16.7)1 (1-2)

IQR: Interquartile range

Comparison of staining intensity in the three study groups OSMF: Oral submucous fibrosis, OSCC: Oral squamous cell carcinoma, IQR: Interquartile range Comparison of staining intensity between malignant and nonmalignant groups IQR: Interquartile range

Labeling intensity

Labeling index values ranged from 0 to 150. Overall mean labeling index was 49.73 ± 26.60. The mean labeling index was minimum for OSMF (26.67 ± 15.05) followed by normal (44.47 ± 6.32) and maximum for OSCC (78.07 ± 22.31) group. On evaluating the data statistically using ANOVA, the intergroup differences were found to be significant statistically (P < 0.001) [Table 4].
Table 4

Comparison of labeling intensity among different groups

Serial numberGroupNumber of casesLabeling intensitySDMinimumMaximum
1Normal1544.476.323655
2OSMF1526.6715.05055
3OSCC1578.0722.3150150
Total4549.7326.600150

OSMF: Oral submucous fibrosis, OSCC: Oral squamous cell carcinoma, SD: Standard deviation

Comparison of labeling intensity among different groups OSMF: Oral submucous fibrosis, OSCC: Oral squamous cell carcinoma, SD: Standard deviation Statistical evaluation of between-group differences was done using Tukey's honestly significant difference test. The mean difference ± standard error between normal and OSMF, normal and OSCC and OSMF and OSCC groups was −17.80 ± 5.83, −33.60 ± 5.83, and −51.40 ± 5.83, respectively. All the between-group differences were significant statistically (P < 0.05). Thus, the order of labeling index scores in different groups was OSMF
Table 5

Comparison of labeling score among different groups

Serial numberGroupNumber of casesLabeling scoreSDMinimumMaximum
1Normal1584.7351.5136165
2OSMF1546.7344.250165
3OSCC15154.4794.7475450
Total4595.3179.740450

OSMF: Oral submucous fibrosis, OSCC: Oral squamous cell carcinoma, SD: Standard deviation, LS: Labeling score

Table 6

Labeling Intensity among different grades of oral squamous cell carcinoma

Serial numberGroupNumber of casesLabeling intensitySDMinimumMaximum
1Well differentiated1280.9224.2450150
2Moderately differentiated267.503.546570
3Poorly differentiated165.00
Total1578.0722.3150150

SD: Standard deviation

Comparison of labeling score among different groups OSMF: Oral submucous fibrosis, OSCC: Oral squamous cell carcinoma, SD: Standard deviation, LS: Labeling score Labeling Intensity among different grades of oral squamous cell carcinoma SD: Standard deviation

Labeling score

Labeling score values ranged from 0 to 450. Overall mean labeling score was 95.31 ± 79.74. The mean labeling score was minimum for OSMF (46.73 ± 44.25) followed by normal (84.73 ± 51.51) and maximum for OSCC (154.47 ± 94.74) group. On evaluating the data statistically using ANOVA, the intergroup differences were found to be significant statistically (P < 0.001). Thus, the order of labeling scores in different groups was OSMF ~ normal < OSCC [Table 7].
Table 7

Labeling score among different grades of oral squamous cell carcinoma

Serial numberGroupNumber of casesLabeling scoreSDMinimumMaximum
1Well differentiated12154.33105.8375450
2Moderately differentiated2167.5038.89140195
3Poorly differentiated1130.00
Total15154.4794.7475450

SD: Standard deviation

Labeling score among different grades of oral squamous cell carcinoma SD: Standard deviation The order of labeling intensity was well-differentiated, moderately differentiated and poorly differentiated respectively, and for labeling scores, the order was poorly differentiated, well-differentiated and moderately differentiated grade [Figure 1].
Figure 1

(a) Normal oral mucosa (H&E, ×100). (b) Well-differentiated oral squamous cell carcinoma (H&E, ×100). (c and d) Immunohistochemical expression of human telomerase reverse transcriptase in well-differentiated oral squamous cell carcinoma ×100, ×400, respectively

(a) Normal oral mucosa (H&E, ×100). (b) Well-differentiated oral squamous cell carcinoma (H&E, ×100). (c and d) Immunohistochemical expression of human telomerase reverse transcriptase in well-differentiated oral squamous cell carcinoma ×100, ×400, respectively

DISCUSSION

The transformation from normal mucosa to cancerous condition is quite eventful involving a number of cytological and molecular changes. These changes are associated with genetic changes that affect cell cycle, apoptosis, angiogenesis and telomere length. Telomeres are the extreme ends of double-stranded eukaryotic chromosomes comprising a tandem array of TTAGGG repeats and DNA-binding proteins. In humans, it consists of repeats of TTAGGG with a 3’ end overhang that helps in the formation of D-loop and T-loop structures. Telomeres protect the chromosomal ends from degradation by exonucleases and prevent recognition as double-stranded DNA breaks, end-to-end fusions and ring chromosome formation. Thus, telomeres play a vital role in the regulation of gene expression, functional organization of the chromosome and in controlling the replicative life of cells and entry into senescence.[18] At the chromosomal level, the telomere activity is controlled and stabilized by a ribonucleoprotein complex called telomerase. The telomerase complex consists of RNA template (hTR), a catalytic subunit called hTERT and associated protein (hTP-1).[19] hTERT expression (molecular weight ~130 kDa) is one of the critical determinants of telomerase activity.[202122] Thus, the study of hTERT can be considered as a surrogate marker of telomerase activity and can help in understanding the transitional pattern from normal tissue to a malignant condition. Considering the weak cytoplasmic expression and taking clues from previous studies, we focused only on the nuclear stains. Nuclear staining was also studied using two parameters – first one was the percentage of stained nuclei in per thousand cells which was termed as labeling intensity and second was a more objective parameter giving due weight to both span (labeling intensity) and intensity (stain intensity) and deriving a score as a product of labeling intensity and stain intensity and was termed as LS. This scoring system was also used by Palani et al. in their study. The use of multiplication product of two semiquantitative parameters helps to convert them into a quantitative parameter and thus provides a greater discriminating efficiency. However, Raghunandan et al. in their study did not use a scoring system based on multiple parameters and banked on measuring differences in different groups on the basis of independent parameters only. However, other workers like Haraguchi et al. and Luzar et al. similar to the present study preferred to use an integrated scoring system for differentiation among different groups.[232425] In the present study, all the cases were males. The reason for this could be the fact that the risk of oral cancer is multifolds in males as compared to females. In Northern India, the incidence of oral cancer is related with the habit of tobacco and gutkha use, both the habits being predominated by males. However, despite this predominance of males, the high proportion of males in the present study is the only incidence and does not reflect any epidemiological risk. Consecutively, in premalignant and control groups, matching was done leading to a study in an all male population. The assessment of hTERT activity was done in terms of SI scores, labeling intensity scores and LS, respectively, as per the criteria described by Palani et al.[15] The location of expression was also noted in terms of nuclear and cytoplasmic localization. Incidentally, the present study found the coexpression of hTERT in both nucleus and cytoplasm in all the cases of all the three groups studied. As far as SI was concerned, we did not find a significant difference among the study groups. On collective assessment between malignant and nonmalignant states too, the difference was not found to be significant statistically. In the present study, the hTERT LSs also failed to discriminate between different grades of OSCC, although previous studies have shown a possible discriminatory role of hTERT expression for differentiation of different grades or stages of OSCC,[162627] primarily owing to a high dominance of well-differentiated OSCC grade (n = 12/15; 80%) as compared to moderately differentiated (n = 2; 13.3%) and poorly differentiated (n = 1/15; 6.7%) cases, thus leaving the scope for incidental findings. Despite certain limitations such as the absence of females, disproportionate distribution of grades and inclusion of only one premalignant condition (OSMF only), the present study made a point that telomerase activity is enhanced in the OSCC cases. In the present study, the labeling intensity which was comparable to the intensity of hTERT staining used by Raghunandan et al.,[23] was minimum in OSMF cases (26.67 ± 15.05) followed by normal oral mucosa (44.47 ± 6.32) and OSCC (78.07 ± 22.31), respectively, and showed a significant intergroup difference.

CONCLUSION

However, owing to these limitations, the present study was able to highlight only the discriminating ability of hTERT for differentiating the malignant condition from premalignant and normal mucosa. Hence, further studies on a larger sample size with the inclusion of other premalignant conditions too are recommended to understand the pattern of hTERT expression changes in different types of premalignant and malignant oral lesions and to understand the probable physiology behind the progression from normal to malignant status.

Financial support and sponsorship

This study was funded by the Intramural Research Grant (Era's Lucknow Medical College and Hospital, Lucknow).

Conflicts of interest

There are no conflicts of interest.
  25 in total

1.  Mapping of the gene for the human telomerase reverse transcriptase, hTERT, to chromosome 5p15.33 by fluorescence in situ hybridization.

Authors:  L A Bryce; N Morrison; S F Hoare; S Muir; W N Keith
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

Review 2.  Structure and function of telomeres.

Authors:  E H Blackburn
Journal:  Nature       Date:  1991-04-18       Impact factor: 49.962

3.  Immunohistochemical detection of human telomerase reverse transcriptase in oral cancer and pre-cancer.

Authors:  Jayanthi Palani; Vidya Lakshminarayanan; Ranganathan Kannan
Journal:  Indian J Dent Res       Date:  2011 Mar-Apr

4.  The RNA component of human telomerase.

Authors:  J Feng; W D Funk; S S Wang; S L Weinrich; A A Avilion; C P Chiu; R R Adams; E Chang; R C Allsopp; J Yu
Journal:  Science       Date:  1995-09-01       Impact factor: 47.728

Review 5.  Socioeconomic inequalities and oral cancer risk: a systematic review and meta-analysis of case-control studies.

Authors:  David I Conway; Mark Petticrew; Helen Marlborough; Julien Berthiller; Mia Hashibe; Lorna M D Macpherson
Journal:  Int J Cancer       Date:  2008-06-15       Impact factor: 7.396

Review 6.  Telomerase: An exploration toward the end of cancer.

Authors:  Deepika Bablani Popli; Keya Sircar; Aman Chowdhry
Journal:  Indian J Dent Res       Date:  2017 Sep-Oct

7.  Specific association of human telomerase activity with immortal cells and cancer.

Authors:  N W Kim; M A Piatyszek; K R Prowse; C B Harley; M D West; P L Ho; G M Coviello; W E Wright; S L Weinrich; J W Shay
Journal:  Science       Date:  1994-12-23       Impact factor: 47.728

8.  Human telomerase reverse transcriptase expression in oral carcinogenesis--a preliminary report.

Authors:  S K S Kumar; R B Zain; S M Ismail; S C Cheong
Journal:  J Exp Clin Cancer Res       Date:  2005-12

9.  A review of research on salivary biomarkers for oral cancer detection.

Authors:  Yi-Shing Lisa Cheng; Terry Rees; John Wright
Journal:  Clin Transl Med       Date:  2014-02-24

10.  Expression of human telomerase reverse transcriptase protein in oral epithelial dysplasia and oral squamous cell carcinoma: An immunohistochemical study.

Authors:  Bangalore Nagarajachar Raghunandan; Karpagaselvi Sanjai; Jayalakshmi Kumaraswamy; Lokesh Papaiah; Bhavna Pandey; Bellur MadhavaRao Jyothi
Journal:  J Oral Maxillofac Pathol       Date:  2016 Jan-Apr
View more
  3 in total

Review 1.  Oral Potentially Malignant Disorders: Etiology, Pathogenesis, and Transformation Into Oral Cancer.

Authors:  Pratima Kumari; Priyanka Debta; Anshuman Dixit
Journal:  Front Pharmacol       Date:  2022-04-20       Impact factor: 5.988

Review 2.  Prognostic and Clinicopathological Significance of Telomerase Reverse Transcriptase Upregulation in Oral Cancer: A Systematic Review and Meta-Analysis.

Authors:  Miguel Ángel González-Moles; Eloísa Moya-González; Alberto García-Ferrera; Paola Nieto-Casado; Pablo Ramos-García
Journal:  Cancers (Basel)       Date:  2022-07-28       Impact factor: 6.575

Review 3.  A Systematic Review of Oral Biopsies, Sample Types, and Detection Techniques Applied in Relation to Oral Cancer Detection.

Authors:  Guanghuan Yang; Luqi Wei; Benjamin K S Thong; Yuanyuan Fu; Io Hong Cheong; Zisis Kozlakidis; Xue Li; Hui Wang; Xiaoguang Li
Journal:  BioTech (Basel)       Date:  2022-03-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.